Denali Therapeutics Reports Q2 2026 Financial Results
Denali Therapeutics (DNLI) announced a second-quarter loss of 68 cents per share on August 8, 2026, which is an improvement from the Zacks Consensus Estimate of a 73-cent loss and a narrower loss compared to 72 cents during the same quarter last year. The company achieved net product revenues of $3.6 million following the U.S. launch of its FDA-approved treatment for Hunter Syndrome, Avlayah, which had just started commercial sales after its approval in March 2026.
In June 2026, Denali sold a Rare Pediatric Disease Priority Review Voucher for $195 million, bolstering its cash reserves, which amounted to approximately $940 million as of June 30, 2026, and surpassing $1.1 billion post-sale. The company projects third-quarter revenues for Avlayah to range between $10 million and $12 million. Denali is also advancing its pipeline with ongoing studies for treatments targeting Sanfilippo syndrome and frontotemporal dementia.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
